Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732275 · ClinicalTrials.gov registry record · Phase 1
DS-3201b in Participants With Lymphomas
A Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant, sponsored by Daiichi Sankyo Co..
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT02732275: Active Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant, sponsored by Daiichi Sankyo Co..
NCT02732275 is a Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant that is active but no longer recruiting, run by Daiichi Sankyo Co.. The registered enrollment target is 100 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02732275, a Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant, is active but no longer recruiting, sponsored by Daiichi Sankyo Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
Primary Outcome
Number of DLT-evaluable participants with protocol-defined DLTs
Conditions Studied
Interventions
- DRUG DS-3201b
Study Locations (20)
New York
- Weill Cornell Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
Kagoshima-ken
- Imamura General Hospital - Kagoshima
- Kagoshima University Hospital - Kagoshima
California
- City of Hope National Medical center - Duarte
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT02732275 still lists
NCT02732275 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which DS-3201b is the first listed.
NCT02732275 names 20 study sites across 18 states, led by New York, Kagoshima-ken, California.
Frequently Asked Questions
What is clinical trial NCT02732275 about?
NCT02732275 is a clinical study titled "DS-3201b in Participants With Lymphomas". DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is d...
What is the current status of trial NCT02732275?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-03-31. Estimated completion is 2026-12-31.
What conditions does trial NCT02732275 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Lymphoma, Malignant.
What interventions are being tested in trial NCT02732275?
The interventions under investigation include: DS-3201b (DRUG).
Who is sponsoring clinical trial NCT02732275?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02732275 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02732275's enrollment target sits among peer trials
100 36th of 106 higher than 68 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI